hematological-systemCRISPR gene editing technology has made significant progress in the treatment of patients with severe beta-thalassemia
CRISPR gene editing treated children with β0/β0 severe thalassemia have been free from blood transfusion dependence for 3 years, according to the research team, this is also the world's first reported successful clinical result of CRISPR gene editing for the treatment of children with severe thalassemia β0/β0 type.
Learn more
